Logo

Exelixis, NCI to Study Anti-Cancer Compounds

Jun 07, 2000
Premium

SOUTH SAN FRANCISCO--Exelixis announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute to elucidate how NCI anti-cancer compounds work. In the three-year collaboration, Exelixis will use its proprietary model system genetics technology to identify the mechanism of action for NCI compounds that have a demonstrated in vivo or in vitro anti-cancer activity. NCI will work with Exelixis to characterize and further develop the compounds for clinical therapeutic potential.

Filed under

Informatics
Breaking News
The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.